Emerald Advisers LLC Makes New Investment in Savara Inc (NASDAQ:SVRA)

Emerald Advisers LLC bought a new stake in shares of Savara Inc (NASDAQ:SVRA) during the fourth quarter, Holdings Channel reports. The fund bought 2,332,680 shares of the company’s stock, valued at approximately $7,161,000.

Several other hedge funds have also recently modified their holdings of SVRA. Cibc World Markets Corp purchased a new position in Savara during the fourth quarter valued at approximately $33,000. KLP Kapitalforvaltning AS bought a new stake in Savara during the 4th quarter valued at $41,000. Virtu Financial LLC purchased a new position in shares of Savara in the 3rd quarter valued at $67,000. BNP Paribas Financial Markets raised its position in shares of Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after purchasing an additional 4,732 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

SVRA opened at $2.82 on Friday. The firm’s 50-day moving average price is $2.73 and its 200-day moving average price is $3.31. The company has a market cap of $483.97 million, a P/E ratio of -6.56 and a beta of 0.60. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 52-week low of $2.26 and a 52-week high of $5.34.

Wall Street Analysts Forecast Growth

SVRA has been the topic of several analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company began coverage on shares of Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.